Regions
MAIN/REGIONS
regions/
Regions
  1. Americas
  2. Asia & Oceania
  3. Europe
  4. Middle East & Africa
  1. Solutions
  2. Products
  3. Insights
  4. About
  5. Careers
  6. Contact Us
MAIN/search
MAIN/Solutions
Solutions/
SOLUTIONS
  • Research & Development
  • Real World Evidence
  • Commercialization
  • Safety & Regulatory Compliance
  • Technologies
LIFE SCIENCE SEGMENTS
HEALTHCARE SEGMENTS
THERAPEUTIC AREAS

Impacting People's Lives

"We strive to help improve outcomes and create a healthier, more sustainable world for people everywhere.

LEARN MORE
Harness the power to transform clinical development

Reimagine clinical development by intelligently connecting data, technology, and analytics to optimize your trials. The result? Faster decision making and reduced risk so you can deliver life-changing therapies faster.

Research & Development Overview
Research & Development Quick Links
Real World Evidence. Real Confidence. Real Results.

Generate and disseminate evidence that answers crucial clinical, regulatory and commercial questions, enabling you to drive smarter decisions and meet your stakeholder needs with confidence.

REAL WORLD EVIDENCE OVERVIEW
Real World Evidence Quick Links
See markets more clearly. Opportunities more often.

Elevate commercial models with precision and speed using AI-driven analytics and technology that illuminate hidden insights in data.

COMMERCIALIZATION OVERVIEW
Commercialization Quick Links
Service driven. Tech-enabled. Integrated compliance.

Orchestrate your success across the complete compliance lifecycle with best-in-class services and solutions for safety, regulatory, quality and medical information.

COMPLIANCE OVERVIEW
Safety & Regulatory Compliance Quick Links
Intelligence that transforms life sciences end-to-end.

When your destination is a healthier world, making intelligent connections between data, technology, and services is your roadmap.

TECHNOLOGIES OVERVIEW
Technology Quick Links
MAIN/Products
Products/
CLINICAL PRODUCTS
COMMERCIAL PRODUCTS
COMPLIANCE, SAFETY, REG PRODUCTS
REAL WORLD PRODUCTS

CASE STUDY

"Data in a Day

LEARN MORE
MAIN/Insights
Insights/
BLOGS, WHITE PAPERS & CASE STUDIES

Explore our library of insights, thought leadership, and the latest topics & trends in healthcare.

DISCOVER INSIGHTS
THE IQVIA INSTITUTE

An in-depth exploration of the global healthcare ecosystem with timely research, insightful analysis, and scientific expertise.

SEE LATEST REPORTS

INSTITUTE REPORT

"Global Trends in R&D 2024

READ MORE

EMEA Insights

"IQVIA thought leadership with a focus on EMEA.

Learn more

WHITE PAPER

"DCTs Deliver Big ROI

LEARN MORE

WHITE PAPER

"Capturing value at scale: The $4 billion RWE imperative

LEARN MORE
MAIN/About
About/
FEATURED INNOVATIONS
  • IQVIA Connected Intelligence™
  • IQVIA Healthcare-grade AI™
  • Human Data Science Cloud
  • IQVIA Innovation Hub
  • Decentralized Trials
  • Patient Experience powered by Apple
WHO WE ARE
NEWS & RESOURCES

INVESTOR RELATIONS

"Visit our investor relations site for more information.

LEARN MORE
Unlock your potential to drive healthcare forward

By making intelligent connections between your needs, our capabilities, and the healthcare ecosystem, we can help you be more agile, accelerate results, and improve patient outcomes.

LEARN MORE
IQVIA AI is Healthcare-grade AI

Building on a rich history of developing AI for healthcare, IQVIA AI connects the right data, technology, and expertise to address the unique needs of healthcare. It's what we call Healthcare-grade AI.

LEARN MORE
Your healthcare data deserves more than just a cloud.

The IQVIA Human Data Science Cloud is our unique capability designed to enable healthcare-grade analytics, tools, and data management solutions to deliver fit-for-purpose global data at scale.

LEARN MORE
Innovations make an impact when bold ideas meet powerful partnerships

The IQVIA Innovation Hub connects start-ups with the extensive IQVIA network of assets, resources, clients, and partners. Together, we can help lead the future of healthcare with the extensive IQVIA network of assets, resources, clients, and partners.

LEARN MORE
Proven, faster DCT solutions

IQVIA Decentralized Trials deliver purpose-built clinical services and technologies that engage the right patients wherever they are. Our hybrid and fully virtual solutions have been used more than any others.

LEARN MORE
IQVIA Patient Experience Solutions powered by Apple

Empowering patients to personalize their healthcare and connecting them to caregivers has the potential to change the care delivery paradigm. IQVIA and Apple are collaborating to bring this exciting future of personalized care directly to devices patients already have and use.

LEARN MORE
MAIN/Careers
Careers/
WORKING AT IQVIA

Our mission is to accelerate innovation for a healthier world. Together, we can solve customer challenges and improve patient lives.

LEARN MORE
LIFE AT IQVIA

Careers, culture and everything in between. Find out what’s going on right here, right now.

LEARN MORE

WE’RE HIRING

"Improving human health requires brave thinkers who are willing to explore new ideas and build on successes. Unleash your potential with us.

SEARCH JOBS
MAIN/Contact Us
Contact Us/
Blog
​Saving Babies with Maternal Vaccines
Claude Hughes, M.D., Ph.D.
Aug 30, 2017
  • Blogs
  • Saving babies with maternal vaccines

Maternal immunity has long been understood to provide vulnerable newborns with antibodies to protect them against some infections as their immune systems mature. However this protection is far from complete. Every year roughly 3.3 million babies die within the first 28 days of life, with more than a third of them succumbing to infections.

The World Health Organization (WHO) specifically targeted this risk in its fourth Millennium Development Goal (MDG 4) to reduce mortality rate by two-thirds among under-five children between 1990 and 2015. And while they made significant progress, more work can be done.

One strategy that has seen success is maternal immunization, or pregnancy vaccines. Maternal immunization is now a clinically validated strategy to prevent infections that afflict very young infants in the first weeks of life. The US Centers for Disease Control (CDC) already recommends that pregnant women get a combined diphtheria, tetanus and whooping cough combination vaccine, as well as a flu vaccine, during each pregnancy. These are just the beginning.

Soon there may be a much broader portfolio of vaccine options to enhance transferal of maternal protective antibodies to infants while still in utero which could have a profound effect on infant mortality rates around the world. Many global pharma companies are investing in the development of maternal immunizations for a variety of infectious diseases, with several conducting early phase trials:

• In June of this year, Pfizer began a phase I/II trial of its maternal group B streptococcus (GBS) vaccine. GBS manifests as sepsis, pneumonia and meningitis in newborns, with potentially fatal outcomes or serious neurological damage. If the vaccine is successful, it could prevent approximately 95 percent of GBS disease in infants via maternal immunization.
• Novavax is currently enrolling patients for a phase III trial of a maternal immunization against Respiratory Syncytial Virus (RSV). RSV is responsible for an estimated 160,000 deaths per year worldwide.
• VBI Vaccines is developing a maternal vaccine to prevent cytomegalovirus (CMV) infection, which is a leading cause of prenatal anomalies and postnatal neurological abnormalities, particularly sensorineural deafness. VBI expects to evaluate safety, tolerability, and also immunological proof of concept in humans during Phase I trials.

In addition to these examples, there are several other companies with maternal vaccines in development for the above indications. We are also seeing studies of the impact of maternal booster vaccines and pre-conception vaccines against other serious infectious diseases, such as a Zika virus vaccine, as well as development of vaccines that do not specifically target pregnant women but may be beneficial in conferring immunity to the infant. One example of this is a potentially effective malaria vaccine.

Obstacles ahead

These maternal vaccines have the potential to save millions of young lives, though sponsors face unique challenges in developing and marketing these treatments. Despite proof that maternal immunization is an effective strategy to prevent infectious diseases in pregnant women and infants, lack of knowledge about these diseases and concerns about the safety of vaccines given during pregnancy have been cited as obstacles to improving rates of maternal immunization.

Because pregnant women have long been excluded from clinical research, it is difficult to overcome some of these concerns and to demonstrate the safety and efficacy of maternal vaccines in a clinical setting. The majority of safety and effectiveness data for existing maternal vaccines come from retrospective population-based cohort studies and database reviews rather than randomized clinical trials (RCTs).

See you in Brussels

In September, experts across the maternal immunization space will come together to discuss these and other topics at the 4th International Neonatal & Maternal Immunization Symposium in Brussels. The event will bring together scientists, clinicians and public health experts from all continents to share data from recent trials, and to discuss opportunities and challenges within the maternal and neonatal immunization space.

Interactive panel discussions and presentations promise to provide a comprehensive scientific and practical update on the latest trends in this space, including sessions on impact of maternal and environmental factors on the effectiveness of vaccines, updates on GBS immunization efforts, and the perception of risk related to maternal and neonatal immunization.

Maternal immunization is the next frontier in vaccine research. As more of these trials see success, we move closer to a world where infant mortality rates will hopefully plummet, and infectious diseases that once killed millions of newborn infants could one day be eradicated.

Related solutions

Pediatrics

The right pediatric program to deliver your medicine sooner.

Therapeutic & Specialty Expertise

Specialized expertise and customized solutions across 14 therapeutic centers of excellence, including oncology, GI/NASH, pediatrics, neurology and rare diseases.

Contact Us